AstraZeneca PLC yesterday announced that it would invest an additional NT$1 billion (US$32.6 million) in Taiwan over the next three years as it gears up to launch 10 new medicines by 2021.
The investment would help the company strengthen its bond with Taiwan, create 140 high-quality scientific jobs and increase its local workforce to 430, the company said.
The expansion would also support an additional 1,000 jobs through contract manufacturing, AstraZeneca Taiwan Ltd general manager Simon Manners told a news conference in Taipei.
The investment would raise the company’s average annual clinical research budget in Taiwan nearly threefold from NT$230 million to more than NT$600 million by 2021.
The company has also inked a letter of intent with BioHub Taiwan to collaborate with the biotechnology start-up incubator in the National Biotechnology Research Park in Taipei’s Nangang District (南港).
AstraZeneca would also collaborate with the Program for Translational Innovation of Biopharmaceutical Development-Technology Supporting Platform Axis, a program led by the science, economic and health ministries to accelerate the commercialization of technologies through effective integration of resources and infrastructure.
In the past five years, the company has invested more than NT$1.4 billion in clinical studies in Taiwan to develop medicines that suit the local genetic profile and treat the leading causes of death.
The company ranks first among its global peers in clinical trials on lung cancer, which has a disproportionately high occurrence rate in Taiwan.
These collaborations represent the company’s commitment to Taiwanese and would support the development of innovative solutions to healthcare challenges, Manners said.
It would also cultivate local talent and raise Taiwan’s profile as a biomedical development hub, he added.
The nation’s exemplary National Health Insurance (NHI) system and its healthcare infrastructure make it the ideal destination to conduct clinical studies and scientific research, medical international vice president Alexander Bedenkov said.
Apart from drug development, the company has initiated two healthcare delivery partnerships with local experts and start-ups to support the nation’s estimated 2 million asthma and 2 million diabetes patients.
“The partnerships we have initiated, such as Healthy Lung and Early Action in Diabetes, aim to improve and prolong patients’ lives and reduce healthcare expenditure,” Asia area president Joris Silon said.
While the Food and Drug Administration’s drug approval process has been efficient in granting priority review to three out of the 10 medicines set to be launched by 2021, the company hopes that its conversations with the government on NHI reimbursement could proceed at a faster pace, Manners said.
Just a few years ago, the millennial generation — generally defined as those born from the early 1980s through the mid-1990s — was synonymous with youthful rebellion. However, now, as the millennials ease into early middle age, they are finding their path out of their parents’ basement to be a lot harder than it was for earlier generations. The fundamental problem is that millennials are not building wealth. The wealth of the median US household headed by someone 35 or younger has actually shrunk in inflation-adjusted terms since the mid-2000s, even as the wealth of older Americans has continued to grow. An
Apple Inc’s decision to stop using Intel Corp processors in its Mac computers and switching to its own chips might benefit Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and boost Taiwan’s high-tech exports, Australia and New Zealand Banking Group (ANZ) said in a note on Tuesday. The US tech giant announced the “Apple silicon” initiative at its annual Worldwide Developers’ Conference, which started on Monday. The company said the first Mac powered by its own chips would debut by the end of this year and all product lines might shift to the new architecture in the next two years. TSMC is likely to
EXPERIMENTAL DRUG: While news about a COVID-19 vaccine is more eye-catching, developing a treatment would be more viable, the Senhwa boss said Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday. That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone. The price of the new shares would depend on the firm’s average share price
Gogoro Inc (睿能創意) yesterday launched its first electric bicycle, the Gogoro Eeyo 1, in Taiwan, after unveiling the bike in New York in late May and in France on Tuesday. The company said it would also introduce the series in other European countries such as Germany and the Netherlands. The “Eeyo project” is the fourth of Gogoro’s eight projects that concentrate on smart transportation, which includes Gogoro’s electric scooter, battery swap system and electric scooter sharing service, company founder and chief executive officer Horace Luke (陸學森) told a media briefing in Taipei. “There are various types of city commuters. We will not